NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM): Analyzing Valuation After FDA Grants Priority Review for Setmelanotide Expansion
Rhythm Pharmaceuticals (RYTM) just received a significant decision from the FDA, as their supplemental New Drug Application for setmelanotide was not only accepted for filing but also granted Priority Review status. This indicates that the agency sees potential for the medication to address an urgent, unmet need for people dealing with acquired hypothalamic obesity. Investors familiar with Rhythm know setmelanotide already has approvals for rare genetic obesity disorders. This proposed...